Suspension of trading

Oncternal Therapeutics, Inc. Share Price

ONCT

US68236P2065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 02/12/2024 GMT			5-day change	1st Jan Change
0.5266 ^USD	-24.11%		-.--%	-

01/07/25	Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
01/07/25	Oncternal Therapeutics, Inc. Announces Management Changes	CI

Valuation: Oncternal Therapeutics, Inc.

Market Cap	1.56M 1.36M 1.26M 1.17M 2.21M 148M 2.25M 15.07M 5.86M 73M 5.85M 5.72M 252M	P/E 2022	-1.19x	P/E 2023	-0.8x
Enterprise Value	-32.38M -28.33M -26.11M -24.2M -45.95M -3.07B -46.69M -313M -122M -1.52B -122M -119M -5.24B	EV / Sales 2022	-4.9x	EV / Sales 2023	-2.95x
Free-Float	90.77%	Yield 2022 *	-	Yield 2023	-

* Estimated data More valuation ratios

Latest news : Oncternal Therapeutics, Inc.

01/07/25	Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
01/07/25	Oncternal Therapeutics, Inc. Announces Management Changes	CI
04/12/24	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from S&P TMI Index	CI
01/12/24	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index	CI
25/11/24	Top Premarket Decliners	MT
06/11/24	Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
23/10/24	Oncternal Therapeutics Continues to Explore Strategic Alternatives	CI
22/10/24	Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	CI
12/09/24	Oncternal Therapeutics, Inc. Announces Discontinue Its Clinical Trials Evaluating ONCT-534	CI
12/09/24	Oncternal Therapeutics, Inc. Announces Workforce Reduction	CI
12/09/24	Oncternal Therapeutics, Inc. Announces Cessation of Salim Yazji as Chief Medical Officer, Effective as of October 1, 2024	CI
12/09/24	Sector Update: Health Care Stocks Rise in Thursday Trading	MT
12/09/24	Oncternal Therapeutics Announces Exploration of Strategic Alternatives	CI

More news

Analysts' recommendations: Oncternal Therapeutics, Inc.

12/09/24	Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy	MT
15/04/24	HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	MT
04/12/23	Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2	MT
18/09/23	HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2	MT
04/04/23	Maxim Downgrades Oncternal Therapeutics to Hold From Buy	MT

More recommendations

Press Releases: Oncternal Therapeutics, Inc.

07/03/25	Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC	AQ
25/11/24	Oncternal Therapeutics : Failure to Satisfy Listing Rule Form 8 K	PU
22/10/24	Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
12/09/24	Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives	AQ
08/08/24	Oncternal Therapeutics: Q2 Earnings Snapshot	AQ

More press releases

Managers and Directors: Oncternal Therapeutics, Inc.

Manager	Title	Age	Since
Richard Vincent DFI	Director of Finance/CFO	63	31/03/2017
Yisrael Katz CTO	Chief Tech/Sci/R&D Officer	-	30/06/2023
Rajesh Krishnan CTO	Chief Tech/Sci/R&D Officer	53	-

Director	Title	Age	Since
David Hale CHM	Chairman	77	30/11/2018
Dan Kisner BRD	Director/Board Member	79	06/06/2019
Rosemary Mazanet BRD	Director/Board Member	70	26/01/2021

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCTERNAL THERAPEUTICS, INC.	-24.11%	-.--%	-.--%	-92.49%	1.56M
LONZA GROUP AG	-1.03%	+5.24%	+2.94%	+9.41%	50.25B
REVOLUTION MEDICINES, INC.	+0.25%	+1.70%	+419.39%	+621.71%	40.39B
IQVIA HOLDINGS INC.	+1.10%	+7.77%	+28.18%	-3.96%	34.38B
BEONE MEDICINES AG	-0.16%	+8.42%	+28.20%	+63.00%	34.4B
CELLTRION, INC.	+1.31%	-0.56%	+5.12%	+33.90%	26.32B
ASCENDIS PHARMA A/S	-0.35%	+0.09%	-	-	16.64B
MEDPACE HOLDINGS, INC.	-3.33%	+3.15%	+71.30%	+131.94%	16.14B
EUROFINS SCIENTIFIC SE	+0.32%	+1.09%	+13.28%	+21.98%	13.71B
IONIS PHARMACEUTICALS, INC.	+3.79%	+8.88%	+106.63%	+106.63%	13.75B
Average	-2.08%	+0.80%	+75.01%	+99.12%	24.6B
Weighted average by Cap.	+0.34%	+4.26%	+95.75%	+141.29%

See all sector performances

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâ€™s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

3 years	0.53	13.14
5 years	0.53	92.6
10 years	0.53	211.2

Date	Insider	Type	Main position	Quantity	% Market Cap.
19/06/24	Rosemary Mazanet	Free	Director	2,200	0.0743%
19/06/24	Dan Kisner	Free	Director	2,200	0.0743%
19/06/24	Jill DeSimone	Free	Director	2,200	0.0743%

	2022	2023
Net sales	1.49M 1.3M 1.2M 1.11M 2.11M 141M 2.15M 14.41M 5.6M 69.79M 5.59M 5.47M 241M	785K 687K 633K 587K 1.11M 74.5M 1.13M 7.59M 2.95M 36.77M 2.95M 2.88M 127M
Net income	-44.17M -38.65M -35.62M -33.02M -62.68M -4.19B -63.69M -427M -166M -2.07B -166M -162M -7.15B	-39.48M -34.55M -31.84M -29.51M -56.02M -3.75B -56.92M -382M -148M -1.85B -148M -145M -6.39B
Net Debt	-63.64M -55.69M -51.32M -47.57M -90.3M -6.04B -91.76M -615M -239M -2.98B -239M -234M -10.3B	-33.94M -29.7M -27.37M -25.37M -48.16M -3.22B -48.93M -328M -128M -1.59B -127M -125M -5.49B

Oncternal Therapeutics, Inc. Share Price

Stocks

ONCT

US68236P2065

Biotechnology & Medical Research

Valuation: Oncternal Therapeutics, Inc.

Latest news : Oncternal Therapeutics, Inc.

Analysts' recommendations: Oncternal Therapeutics, Inc.

Press Releases: Oncternal Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Oncternal Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates